Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NK-92

Cell therapy (NK cells) · Kills target cells, directed at tumor cells · developed by ImmunityBio

Phase 2 Most advanced trial

IBRX Developer

2 Registered trials

What is NK-92?

NK-92 is an allogeneic natural killer cell therapy derived from a human cell line, engineered to lack killer inhibitory receptors and express high-affinity Fc receptors and PD-L1. The cells recognize and kill tumor cells through perforin and granzyme release, and enhance antibody-dependent cellular cytotoxicity. It is studied in pancreatic cancer and non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: PD-L1 t-haNK, haNK
Drug type: Cell therapy (NK cells)
Targets: tumor cells (antigen)
Mechanism: Kills target cells, directed at tumor cells
Pathways: ADCC, apoptosis, cytotoxicity
Therapy area: Oncology
Developer: ImmunityBio, Inc. (IBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: Y0EW4890B4

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04390399	Phase 2	Pancreatic Cancer	Active not recruiting	IBRX
NCT03169790	Phase 1/2	Non Hodgkin Lymphoma	Withdrawn	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic CancerNon Hodgkin Lymphoma

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 Adenoviral Vector Ad5-CEA Vaccine Phase 1/2 agenT-797 Phase 3 Aldoxorubicin Phase 2 CD19 t-haNK Phase 2 ETBX-021 Phase 1/2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 ETBX-071 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind NK-92

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z